# A Study of IBI353 (Orismilast) in Chinese Healthy Adults

> **NCT05490316** · PHASE1 · COMPLETED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 20 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** IBI353 (Orismilast)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT05490316
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-30
- **Primary completion:** 2022-11-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05490316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05490316, "A Study of IBI353 (Orismilast) in Chinese Healthy Adults". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05490316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*